Download PDF
Deutsche Zeitschrift für Onkologie 2013; 45(02): 55-61
DOI: 10.1055/s-0033-1334368
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Zirkulierende Tumorzellen − bereits klinische Routine oder noch Forschungsobjekt?

Klinische Relevanz von zirkulierenden Tumorzellen aus peripherem Blut am Beispiel des Mammakarzinoms
Carsten Hagenbeck
1   Universität Düsseldorf, Frauenklinik, Moorenstr. 5, 40225 Düsseldorf
,
Natalia Krawczyk
1   Universität Düsseldorf, Frauenklinik, Moorenstr. 5, 40225 Düsseldorf
,
Carola Melcher
1   Universität Düsseldorf, Frauenklinik, Moorenstr. 5, 40225 Düsseldorf
,
Bernadette Jäger
2   Universität Ulm, Frauenklinik, Prittwitzstr. 43, 89075 Ulm
,
Malgorzata Banys
3   Marienkrankenhaus Hamburg, Frauenklinik, Alfredstr. 9, 22087 Hamburg
4   Universität Tübingen, Frauenklinik, Calwer Straße 7, 72076 Tübingen
,
Andreas Hartkopf
4   Universität Tübingen, Frauenklinik, Calwer Straße 7, 72076 Tübingen
,
Tanja Fehm
1   Universität Düsseldorf, Frauenklinik, Moorenstr. 5, 40225 Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2013 (online)

    Permissions and Reprints

Zusammenfassung

Disseminierte Tumorzellen (DTZ) im Knochenmark können bei 30−40 % aller Patientinnen mit primärem Mammakarzinom entdeckt werden. Der Nachweis disseminierter Tumorzellen zum Zeitpunkt der Erstdiagnose sowie deren Persistenz unter Therapie sind ungünstige prognostische Faktoren. Die Bestimmung zirkulierender Tumorzellen (ZTZ) durch periphere Blutentnahme stellt eine methodische Vereinfachung gegenüber Knochenmarkspunktionen dar, nicht zuletzt im Sinne des Patienten. Zirkulierende Tumorzellen können, je nach Analysemethode und Stadium der Erkrankung, bei 10−80 % aller Patientinnen entdeckt werden. ZTZ sind sowohl für Patientinnen mit primärer wie auch metastasierter Brustkrebserkrankung von prognostischer Bedeutung. Durch die Charakterisierung zirkulierender Tumorzellen könnten etablierte Therapieoptionen angepasst und neue Angriffspunkte zielgerichteter Therapieformen geschaffen werden. Des Weiteren lässt sich mithilfe der ZTZ möglicherweise ein Therapieansprechen evaluieren.

Summary

The detection of disseminated tumor cells in bone marrow is a common phenomenon seen in 30−40 % of primary breast cancer patients. Presence of disseminated tumor cells at time of diagnosis as well as persistent tumor cells following therapy are unfavorable prognostic factors. The evaluation of circulating tumor cells in peripheral blood might become a desired alternative to bone marrow biopsy. Circulating tumor cells are detected, depending on stage of the disease and methodology, in 10−80 % breast cancer patients. Their prognostic relevance has been demonstrated in adjuvant and metastatic setting. Detection and characterization of circulating tumor cells may become an important biomarker for therapy monitoring and specific targeting of minimal residual disease.

Schlüsselwörter

zirkulierende Tumorzellen - disseminierte Tumorzellen - minimale Tumorresterkrankung - Mammakarzinom - Prognose

Keywords

circulating tumor cells - disseminated tumor cells - minimal residual disease - breast cancer - prognosis
 

  • Literatur

  • 1 Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clinical chemistry 2013; 59: 110-118
    CrossrefPubMedGoogle Scholar
  • 2 Ashworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J 1869; 14
    PubMedGoogle Scholar
  • 3 Banys M, Krawczyk N, Becker S et al The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2011; 13 228
    PubMedGoogle Scholar
  • 4 Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 2007; 106(2): 239-243
    CrossrefPubMedGoogle Scholar
  • 5 Benoy IH, Elst H, Philips M et al Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94: 672-680
    PubMedGoogle Scholar
  • 6 Bernhard H, Neudorfer J, Gebhard K et al Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer immunology, immunotherapy CII 2008; 57: 271-280
    PubMedGoogle Scholar
  • 7 Bidard FC, Mathiot C, Delaloge S et al Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-733
    CrossrefPubMedGoogle Scholar
  • 8 Bidard FC, Vincent-Salomon A, Sigal-Zafrani B et al Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008; 19: 496-500
    PubMedGoogle Scholar
  • 9 Braun S, Pantel K, Muller P et al Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533
    CrossrefPubMedGoogle Scholar
  • 10 Braun S, Vogl FD, Naume B et al A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802
    CrossrefPubMedGoogle Scholar
  • 11 Budd GT, Cristofanilli M, Ellis MJ et al Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409
    CrossrefPubMedGoogle Scholar
  • 12 Cristofanilli M, Budd GT, Ellis MJ et al Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791
    CrossrefPubMedGoogle Scholar
  • 13 Cristofanilli M, Hayes DF, Budd GT et al Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430
    CrossrefPubMedGoogle Scholar
  • 14 Daskalaki A, Agelaki S, Perraki M et al Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009; 101: 589-597
    CrossrefPubMedGoogle Scholar
  • 15 Demel U, Tilz GP, Foeldes-Papp Z et al Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. J Exp Clin Cancer Res 2004; 23: 465-468
    PubMedGoogle Scholar
  • 16 Diel IJ, Kaufmann M, Costa SD et al Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1658
    CrossrefPubMedGoogle Scholar
  • 17 Fehm T, Hoffmann O, Aktas B et al Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11: R59
    CrossrefPubMedGoogle Scholar
  • 18 Fehm T, Krawczyk N, Solomayer EF et al ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76
    CrossrefPubMedGoogle Scholar
  • 19 Fehm T, Solomayer EF, Meng S et al Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7: 171-185
    CrossrefPubMedGoogle Scholar
  • 20 Franken B, de Groot MR, Mastboom WJ et al Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012; 14: R133
    CrossrefPubMedGoogle Scholar
  • 21 Gebauer G, Fehm T, Merkle E et al Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-3674
    PubMedGoogle Scholar
  • 22 Giordano A, Giuliano M. De Laurentiis M et al Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23: 1144-1150
    CrossrefPubMedGoogle Scholar
  • 23 Giuliano M, Giordano A, Jackson S et al Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67
    CrossrefPubMedGoogle Scholar
  • 24 Hall C, Krishnamurthy S, Lodhi A et al Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 2012; 118: 342-348
    CrossrefPubMedGoogle Scholar
  • 25 Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571
    CrossrefPubMedGoogle Scholar
  • 26 Hayes DF, Cristofanilli M, Budd GT et al Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-4224
    CrossrefPubMedGoogle Scholar
  • 27 Janni W, Vogl FD, Wiedswang G et al Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clinical cancer research : an official journal of the American Association for Cancer Research 2011; 17. 2967-2976
    Google Scholar
  • 28 Kasprowicz N, Hohnisch E, Raba K et al Die Leukapherese - ein neuer Ansatz zur effektiven Gewinnung von zirkulierenden Tumorzellen bei Mammakarzinom-Patientinnen. Senologie Zeitschrift für Mammadiagnostik und -therapie 2012; 9: A83
    PubMedGoogle Scholar
  • 29 Krawczyk N, Banys M, Neubauer H et al HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 2009; 29: 4019-4024
    PubMedGoogle Scholar
  • 30 Lankiewicz S, Rivero BG, Bocher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol Biotechnol 2006; 34: 15-27
    CrossrefPubMedGoogle Scholar
  • 31 Liu MC, Shields PG, Warren RD et al Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27: 5153-5159
    CrossrefPubMedGoogle Scholar
  • 32 Mansi JL, Gogas H, Bliss JM et al Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999; 354: 197-202
    CrossrefPubMedGoogle Scholar
  • 33 Mathiesen RR, Borgen E, Renolen A et al Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast cancer research: BCR; 2012. 14. R117
    Google Scholar
  • 34 Meng S, Tripathy D, Shete S et al HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101: 9393-9398
    CrossrefPubMedGoogle Scholar
  • 35 Molino A, Pelosi G, Turazza M et al Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 1997; 42: 23-30
    CrossrefPubMedGoogle Scholar
  • 36 Molloy TJ, Bosma AJ, Baumbusch LO et al The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 2011; 13: R61
    CrossrefPubMedGoogle Scholar
  • 37 Muller V, Riethdorf S, Rack B et al Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14: R118
    CrossrefPubMedGoogle Scholar
  • 38 Nakamura S, Yagata H, Ohno S et al Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204
    CrossrefPubMedGoogle Scholar
  • 39 Nieto Y, Franklin WA, Jones RB et al Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 2004; 10: 415-425
    CrossrefPubMedGoogle Scholar
  • 40 Nole F, Munzone E, Zorzino L et al Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897
    CrossrefPubMedGoogle Scholar
  • 41 Ntoulia M, Stathopoulou A, Ignatiadis M et al Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006; 39: 879-887
    CrossrefPubMedGoogle Scholar
  • 42 Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1889; 1 571
    PubMedGoogle Scholar
  • 43 Pestrin M, Bessi S, Galardi F et al Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118: 523-530
    CrossrefPubMedGoogle Scholar
  • 44 Pierga JY, Bidard FC, Mathiot C et al Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004-7010
    CrossrefPubMedGoogle Scholar
  • 45 Pierga JY, Bonneton C, Vincent-Salomon A et al Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004; 10: 1392-1400
    CrossrefPubMedGoogle Scholar
  • 46 Pierga JY, Hajage D, Bachelot T et al High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624
    CrossrefPubMedGoogle Scholar
  • 47 Pierga JY, Petit T, Delozier T et al Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13: 375-384
    CrossrefPubMedGoogle Scholar
  • 48 Rack B, Juckstock J, Gunthner-Biller M et al Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet 2012; 285: 485-492
    CrossrefPubMedGoogle Scholar
  • 49 Rack B, Schindlbeck C, Andergassen U et al Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients. 33rd Annual San Antonio Breast Cancer Symposium 2010; abstr S6−5
    PubMedGoogle Scholar
  • 50 Rack BK, Schindlbeck C, Andergassen U et al Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. ASCO Annual Meeting 2010. J Clin Oncol 2010; 28 15s (suppl; abstr 1003)
    PubMedGoogle Scholar
  • 51 Reinholz MM, Kitzmann KA, Tenner K et al Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in north central cancer treatment group trials, n0234/336/436/437. Clin Cancer Res 2011; 17: 7183-7193
    CrossrefPubMedGoogle Scholar
  • 52 Riethdorf S, Muller V, Zhang L et al Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645
    CrossrefPubMedGoogle Scholar
  • 53 Schmidt-Kittler O, Ragg T, Daskalakis A et al From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 7737-7742
    CrossrefPubMedGoogle Scholar
  • 54 Serrano MJ, Rovira PS, Martinez-Zubiaurre I et al Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 2012; 4: 43-48
    PubMedGoogle Scholar
  • 55 Solomayer EF, Becker S, Pergola-Becker G et al Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006; 98: 179-184
    CrossrefPubMedGoogle Scholar
  • 56 Southwest Oncology Group (SWOG). Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy. In: National Cancer Institute Clinical Trials ed. clinicaltrials.gov/show/NCT00382018
    PubMedGoogle Scholar
  • 57 Stathopoulou A, Vlachonikolis I, Mavroudis D et al Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-3412
    CrossrefPubMedGoogle Scholar
  • 58 Tewes M, Aktas B, Welt A et al Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related thera- pies. Breast Cancer Res Treat 2009; 115: 581-590
    CrossrefPubMedGoogle Scholar
  • 59 Wallwiener M, Hartkopf AD, Baccelli I et al The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013; 137: 503-510
    CrossrefPubMedGoogle Scholar
  • 60 Wiedswang G, Borgen E, Karesen R et al Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003; 21: 3469-3478
    CrossrefPubMedGoogle Scholar
  • 61 Xenidis N, Perraki M, Kafousi M et al Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-3762
    CrossrefPubMedGoogle Scholar
  • 62 Zach O, Kasparu H, Wagner H, Krieger O, Lutz D. Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med Austriaca Suppl 2002; 59: 32-34
    PubMedGoogle Scholar